Xadago® (safinamide) – New drug approval
March 21, 2017 – The FDA announced the approval of Newron Pharmaceuticals’ Xadago (safinamide), indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
Download PDF
